

UPPER TRACT UROTHELIAL CARCINOMAS (UTUCS) PATIENT INSIGHT WEBINAR



SPEAKER DISCLOSURES & BIO'S

Gary D. Steinberg, MD, University of Chicago Medical Center

Disclosure Statement | Scientific advisor for: Cold Genesys, Heat Biologics, FKD, Taris Biomedical, Photocure, Roche/Genentech, FIDA, Synergo, Boston Scientific, Merck, Karl Storz, Urogen, Biocancell, EpiVax Oncology, MDxHealth, Natera

Gary D. Steinberg, MD, is the Bruce and Beth White Family Professor of Urologic Oncology, and Vice Chairman and Director of Urologic Oncology in the Section of Urology at the University of Chicago Comprehensive Cancer Center, University of Chicago Medical Center, in Chicago, Illinois. After receiving his medical degree from the University of Chicago Pritzker School of Medicine, he completed his internship and junior residency in surgery, as well as a residency in urology at the Johns Hopkins Hospital in Baltimore, Maryland. While at Johns Hopkins, he was an American Cancer Society clinical fellow in urologic oncology. Dr. Steinberg's professional interests include bladder cancer and translational clinical research, which he has lectured on around the world.

Dr. Steinberg has served as the principal investigator or co-investigator on more than 45 clinical trials that evaluated pharmaceutical entities; treatment paradigms; and procedures for bladder cancer and other malignancies. He has authored or coauthored more than 200 articles in journals such as Journal of Urology, Urology, and Urologic Oncology, as well as nearly 2 dozen chapters for medical textbooks. Currently, he currently serves on the editorial board of the multiple urologic oncology journals. Dr. Steinberg is chair of the Scientific Advisory Board of the Bladder Cancer Advocacy Network, as well as of the executive committee of the Bladder Cancer Research Network. He is also a member of ASCO, the Society of Urologic Oncology, and AUA, among others.

Karim Chamie, MD, MSHS, Assistant Professor, UCLA Department of Urology

Disclosure Statement | Scientific advisor for: Heat Biologics, Altor

Dr. Chamie is an Assistant Professor-in-Residence of Urology at UCLA. He attended Medical School at USC and completed Urological training at UC Davis. Dr. Chamie then completed a SUO certified fellowship in Urologic Oncology at UCLA. His primary research interests are health services research and clinical trials in bladder cancer. His clinical interests include all areas of urologic oncology, with a particular emphasis on bladder cancer and robotic surgery.

Alon Weizer, MD, Associate Professor, Urology, University of Michigan Medicine

Disclosure Statement | No disclosures to report

After completing his residency at Duke University, Dr. Weizer came to Ann Arbor in 2005 to do a two-year fellowship in Urologic Oncology and minimally invasive surgery. After joining the faculty in 2007, he completed a two year Masters in Clinical Research, Statistical Design and Analysis through the Rackham Graduate School at University of Michigan. Currently he is an Associate Professor of Urology with a focus in Urologic Oncology and Robotic Surgery. Clinically, the majority of his practice is focused on taking care of bladder, kidney, and testis cancer patients.

Dr. Weizer's main research focus is on clinical trials and translational research. He currently has several clinical trials related to diagnosis, surveillance and novel therapies for both non-muscle invasive and invasive bladder cancer. He is also actively involved in the U. Michigan bladder cancer research program and collaborates with colleagues throughout the medical center investigating novel methods to risk stratify patients with bladder cancer. As part of his interest in bladder cancer, he is the physician lead of the University of Michigan Bladder Cancer Clinical Innovation Program which is geared to improving processes to care for this complex patient population.

Ahmad Shabsigh, MD, Assistant Professor of Urology at The Ohio State University.

Disclosure Statement | Primary Investigator for Urogen Mitogel

Dr. Shabsigh is a board certified urologist, subspecializing in urologic cancer.
Fellow in Urologic Oncology Memorial Sloan Kettering Cancer Center 2005-2008
Residency training, New York Presbyterian Medical Center 2000-2005
Research Fellow/Scientist 1996-2000

Jennifer A. Linehan, MD, Associate Professor Urology and Urologic Oncology, Providence St. John's Health Center

Disclosure Statement | No disclosures to report

Jennifer Linehan, M.D., is a board-certified urologist, and is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute. Dr. Linehan completed her medical degree at the College of Medicine at the University of Arizona. She subsequently completed a general surgery internship and then urology residency at the University of Arizona where she received the George M. Drach Award for the most compassionate urologic resident. At the time, she also received awards for research in diagnosis and management of kidney cancer. She joined City of Hope in 2010 as a fellow in robotic and urologic oncology then joined the staff in the City of Hope Medical Group. She is an experienced robotic and laparoscopic surgeon who also has interest in endoscopy for ureteral cancers.

Dr. Linehan has been involved in prostate cancer research. She has worked closely with Steven Smith, Ph.D., at Beckman Research Institute of City of Hope on identifying biomarkers for prostate cancer. She has expanded her research efforts to renal and ureteral tumors identifying biomarkers both in blood and urine with Dr. Hoon, Ph.D at JWCI. She is currently investigating new treatments for bladder cancer.

Surena F. Matin, MD, Professor , Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Disclosure Statement | Consultant: Urogen, Taris, Peloton, C-SATS

Dr. Matin is Professor of Urology in the department of urology and medical director of the minimally invasive new technology in oncologic surgery collaborative program in the division of surgery at MD Anderson cancer center. He is the recipient of the Monteleone Family foundation chair for research in bladder and kidney cancer. Dr. Matin has a high volume practice for patients with UTUC and also has active clinical and translational research activity for this disease.

Seth P. Lerner, MD, FACS, Professor, Scott Department of Urology, Baylor College of Medicine Medical Center

Disclosure Statement |Clinical Trials: Endo, FKD, JBL (SWOG), Roche/Genentech (SWOG), Viventia. Advisory Board: Incyte, Nucleix. Consultant | BioCancell, UroGen, Vaxiion

Dr. Lerner, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He earned his M.D. degree from Baylor College of Medicine and completed two years of General Surgery training at Virginia Mason Clinic in Seattle before returning to Baylor to complete his residency training in Urology. After a one-year AFUD/National Kidney Foundation fellowship and a one-year American Cancer Society fellowship in urologic oncology at the University of Southern California, he returned to Houston in 1992 to join the faculty of the Scott Department of Urology.

Scholar and teacher, author of more than 140 peer-reviewed articles, and co-editor of a widely used comprehensive Textbook of Bladder Cancer, Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America.” He is co-chair of the National Cancer Institute’s Bladder Cancer Task Force and bladder cancer disease working group for The Cancer Genome Atlas Project. He chairs the Local Bladder Committee of SWOG and serves on the Board of Directors for the Bladder Cancer Advocacy Network and winner of BCAN’s 2017 Bladder Cancer Research Innovation Award. He is active in international CME programs for the AUA, SUO, and ASCO and has served as Visiting Professor in places as varied as China, Australia, Germany, and Turkey. He directs the bladder cancer research program at Baylor and is founder of the Bladder Cancer Research Consortium.